(Q38381910)

2 September 2017

title

Silk route to the acceptance and re-implementation of bacteriophage therapy (English)

1 reference

ORCID Public Data File 2021

2 September 2017

1 reference

1 reference

0 references

1 reference

author name string

Expert round table on acceptance and re-implementation of bacteriophage therapy

series ordinal

1

1 reference

2 September 2017

language of work or name

1 reference

23 March 2016

1 reference

2 September 2017

published in

Biotechnology Journal

1 reference

2 September 2017

volume

11

1 reference

2 September 2017

issue

5

1 reference

2 September 2017

page(s)

595-600

1 reference

Diversity, stability and resilience of the human gut microbiota

2 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1002%2FBIOT.201600023

Quality and safety requirements for sustainable phage therapy products

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FBIOT.201600023

Viral host-adaptation: insights from evolution experiments with phages

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FBIOT.201600023

Pre-adapting parasitic phages to a pathogen leads to increased pathogen clearance and lowered resistance evolution with Pseudomonas aeruginosa cystic fibrosis bacterial isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FBIOT.201600023

Synergistic action of gentamicin and bacteriophage in a continuous culture population of Staphylococcus aureus

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FBIOT.201600023

Bacteriophages as biocontrol agents of food pathogens.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FBIOT.201600023

Temperate and lytic bacteriophages programmed to sensitize and kill antibiotic-resistant bacteria.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FBIOT.201600023

Mapping the tail fiber as the receptor binding protein responsible for differential host specificity of Pseudomonas aeruginosa bacteriophages PaP1 and JG004.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FBIOT.201600023

Dispersing biofilms with engineered enzymatic bacteriophage

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FBIOT.201600023

Use of genetically engineered phage to deliver antimicrobial agents to bacteria: an alternative therapy for treatment of bacterial infections.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FBIOT.201600023

Engineered bacteriophage targeting gene networks as adjuvants for antibiotic therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FBIOT.201600023

Selection and characterization of a candidate therapeutic bacteriophage that lyses the Escherichia coli O104:H4 strain from the 2011 outbreak in Germany

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FBIOT.201600023

Optimizing the European regulatory framework for sustainable bacteriophage therapy in human medicine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FBIOT.201600023

Patent pools and clearinghouses in the life sciences.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FBIOT.201600023

21 January 2018

Identifiers

DOI

10.1002/BIOT.201600023

1 reference

2 September 2017

1 reference